Juan Esteban García-Robledo

Also affiliated with Fundación Valle del Lili, Instituto Nacional de Cancerología, Mayo Clinic in Arizona

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576”.

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Advances in Hematology(2022)10.1155/2022/4450824

N/A

0.308DataRank · unranked

3 citations

Paula A. Lengerke-Diaz, Juliana Vélez Luján, Michael Y. Choi, Eider Moreno-Cortes, José Vicente Forero-Forero +7 more

Ibrutinib plus obinutuzumab as frontline therapy for chronic lymphocytic leukemia is associated with a lower rate of infusion-related reactions and with sustained remissions after ibrutinib discontinuation: a single-arm, open-label, phase 1b/2 clinical trial NCT0231576

Research Square(2021)10.21203/rs.3.rs-887972/v1

N/A

0DataRank · unranked

0 citations

Paula A. Lengerke-Diaz, Juliana Velez-Lujan, Michale Y. Choi, Eider Moreno-Cortes, José Vicente Forero-Forero +7 more